All News

Yesho et al. TriNetX study. 24,142 patients. DMARD+GLP-1 in RA reduces malignancy risk compared to DMARD alone. Lung cancer and non-Hodgkins lymphoma predominantly. @RheumNow #ACR26 Abstr#1898 https://t.co/M98SFXlslZ

https://x.com/RichardPAConway/status/2119887499837186405/photo/1

In matched RA pts on DMARDs (TriNetX, n=24,142), GLP-1 RA use was linked to less lung cancer (HR 0.62) and NHL (HR 0.47) at 5 years. Weight loss, less inflammation, or healthier pts getting the drug? Retrospective, so association only. A#1898 @RheumNow #ACR26

#GCA #Flares in year 2 Of #upadacitinib in remission at end of yr 1 Randomized to UPA-UPA Vs UPA-PBO No surprise, on Yr2 PBO ⬆️flares ⬆️pred ⬆️CRP & ESR if flare but higher in no Rx group Take home Rx likely needed for 2 yrs in #GCA #ACR26 @RheumNow @ACRheum #abst1892

Fiber prebiotic for RA? #ACR26 @RheumNow 1 month high fiber intervention reduces pro-inflammatory cytokines 54 pts active RA given fiber supplement. Decrease DAS28 4->3.1, p=0.04 RCT of inulin - impr DAS28 (p=.02), TJC, SJC, CRP. Not in VAS pain/ESR https://t.co/rWvVdGy0EP

Data for probiotics - RA- reduces CRP, mixed dis activity data -SLE- may improve SLEDAI-2K -AS/PSA- no effect -SSc- may help reflux Safety: Common - gas, bloating, diarrhea Caution in severe immunocomp, neutropenia, critical illness & major intest barrier disrupt #ACR26 @RheumNow https://t.co/tEirCu1cdb

https://x.com/ericdeinmd/status/2119857218573173178/photo/1

#ACR26 @RheumNow Probiotics/synbiotics in RA trials -3 trials, 46 to 60 patients, 8 wks All showed improvements of DAS28, VAS pain, hs-CRP, TNF, IL12, but only 1 w/ clinically meaningful response -2 negative trials. No signif benefit in ACR20, DAS28 https://t.co/01h0sR6c9d

Who WON’T get #rheumatoid #arthritis In #CCP+ w #MSK #pain #cohort of ‘#RA at risk’ 82% w3 baseline protective factors don’t progress to RA If all 5 NONE progress 5-10 yrs N #ESR #TJC 0 or 1 Neg #RF No #tenosynovitis Low CCP need to follow? #1835 #ACR26 @RheumNow @ACRheum https://t.co/HpmgvHKLHf

Presence and impact of FMS on disease activity, functioning, and quality of life in SpA patients : Single center cross sectional study from India. 151 pts, low prevalence of FM (9.3%) but mostly female. Pt had worse scores on disease activity indices and patient reported https://t.co/2bw3L7Q7kE

https://x.com/AdelaCastro222/status/2119852965934637345/photo/1

DM-ILD pts enrolled in Ph3 brepocitinib (VALOR) trial encompassed 20% of study population. Subgroup analysis sees improvements in TIS and steroid sparing effect regardless of ILD status. Abstract 1586, #ACR26 @RheumNow https://t.co/oKebDrAE9E

https://x.com/rheumPAC/status/2119851880583221307/photo/1

McDermott et al. 4000 patients. Respiratory infections associated subsequent RA-ILD. @RheumNow #ACR26 Abstr#1737 https://t.co/fWpNWveIbI

https://x.com/RichardPAConway/status/2119848744371782045/photo/1

SCOOT study. S/C MTX better than split dose oral. 252 patients. Odds of EULAR mod/good response at 16 weeks significantly lower with oral split-dose (adjusted OR 0.55, p=0.049). EULAR good response (OR 0.53, p=0.032), ACR50 (OR 0.51, p=0.011) @RheumNow #ACR26 Abstr#1416 https://t.co/1w4VU1qn0p

https://x.com/RichardPAConway/status/2119844214578262154/photo/1

CDAI fell 15 to 8 after GLP1 in an RA cohort. CDAI improvement not significantly assoc with BMI reduction, diabetes, or change in treatment, suggesting observed improvement in disease activity may not be solely explained by weight loss or metabolic effects. #1410 @Rheumnow #ACR26

Carrera-Cruz et al. (RA muscle-adiposity study): In RA, BMI misses muscle quality. An ACR2026 study compared obesity with dynapenia and sarcopenic obesity using DXA and grip strength. Weight-loss care should protect function and strength. @rheumnow #ACR2026 Abstract#1804 https://t.co/bGRwvkZpAt

https://x.com/Gibson_RheumPAC/status/2119843073748500881/photo/1

BSR PsA Register, 815 UK patients starting a b/tsDMARD: 65% remained on drug, and MDA and ACR50 at 12 months were each 24%. Key finding: higher BMI, enthesitis and polysymptomatic distress predicted discontinuation, and concomitant csDMARD use was protective. @rheumnow #ACR26

Prevalence of SpA features in IBD: -Meta-analysis of 81 studies (>110,000 IBD patients, 23 countries): pooled prevalence of SpA features in IBD was 13.4% for peripheral arthritis, 8.9% for sacroiliitis and 3.5% for AS. -Twelve studies contributed incidence data: the largest https://t.co/77hqhWaPi9

Kim et al. Korean single-centre study 664 patients. RA-ILD associated with 7-fold increase in risk of lung cancer compared to RA alone. @RheumNow #ACR26 Abstr#1888 https://t.co/Y8XFDgANi5

https://x.com/RichardPAConway/status/2119831883383185414/photo/1

Ibis et al. GLP-1 agonists in RA associated lower risk of pulmonary hypertension, resp failure, mech ventilation, all-cause mortality (but not ILD). @RheumNow #ACR26 Abstr#1445 https://t.co/0E8qCFJTup

https://x.com/RichardPAConway/status/2119831883328422144/photo/1

How well do we do glucocorticoid-induced osteoporosis in RA? @earlyarthritis cohort of RA in >50yo, PNL ≤7.5 for >3mo guidance suggested 1. Ca supp 2. vit D supp 3. BMD or OP Rx Performance not great but I'm sure I've done no better Needs work! ABST1783 #ACR26 @RheumNow https://t.co/8L2CnOoCXQ

https://x.com/drdavidliew/status/2119829115071005109/photo/1

Singh et al. VA study. 81505 patients. HCQ associated reduced mortality in SLE and RA (but not OA). @RheumNow #ACR26 Abstr#1415 https://t.co/c0epUWxjoj

https://x.com/RichardPAConway/status/2119827856805298599/photo/1

Natalucci et al. Case series combination JAKi and bDMARD in multi-refractory RA (6 patients) (and 1 PsA, 1 SpA) @RheumNow #ACR26 Abstr#1403 https://t.co/vGrwzbd5y1

https://x.com/RichardPAConway/status/2119826850235167007/photo/1

Topics

All News

Do you get our email newsletter?